FMP

FMP

Enter

CBAY - CymaBay Therapeutics...

Financial Summary of CymaBay Therapeutics, Inc.(CBAY), CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and pr

photo-url-https://financialmodelingprep.com/image-stock/CBAY.png

CymaBay Therapeutics, Inc.

CBAY

NASDAQ

Inactive Equity

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

32.48 USD

0.01 (0.03079%)

About

ceo

Mr. Sujal A. Shah

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladel...

CIK

0001042074

ISIN

US23257D1037

CUSIP

23257D103

Address

7575 Gateway Boulevard

Phone

510 293 8800

Country

US

Employee

101

IPO Date

Feb 3, 2014

Summary

CIK

0001042074

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

23257D103

ISIN

US23257D1037

Country

US

Price

32.48

Beta

0.32

Volume Avg.

3.94M

Market Cap

3.73B

Shares

-

52-Week

7.261-32.5

DCF

4.85

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-32.81

P/B

-

Website

https://www.cymabay.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest CBAY News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep